glp 1 vs glp 1ra Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management THE UNSEEN CONSEQUENCES OF GLUCAGON-LIKE

The researchers used electronic health record data from OneFlorida+ a health research network that includes 10 health systems and clinical partners that serve nearly 20 million patients in Florida, Georgia and Alabama to identify adults who were eligible for anti-obesity medications and had no cancer history

After amplification, concentrations were determined based on the proportion of nonfluorescent partitions through the Poisson distribution

Third-party testing isn't standardized

No therapeutic or cosmetic claims are made or implied

The preparation is standardised prior to use, allowing researchers to work with a consistent peptide composition and eliminating variability associated with solution preparation

Bland JS et al